Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market

Pharma IQ News

Moderate Growth Rate and Increasing Competition for the Therapeutic Proteins Market

The global therapeutic proteins market will grow at a moderate pace, with monoclonal antibodies considered to be the highest revenue generating market in 2010. This will also be the leading market in the coming years. The global therapeutic proteins market was worth $93 billion in 2010 and is forecast to grow to $141.5 billion by 2017, which represents a growth rate of 6.2% between 2010 and 2017. With the advancements in the biogenerics and gene therapy markets, the therapeutic proteins market is expected to show a moderate growth rate in the coming years. On the other hand, the introduction of new oral therapeutic proteins will increase the patient pool due to better drug compliance. Even though the competition from gene therapy and the biogenerics market will influence the market, the market is still very attractive for the pharmaceutical companies. 

Moderate Pipeline and the Entry of New Players will Intensify the Competition

The therapeutic proteins market has a moderate pipeline base, supporting growth in the market and thereby attracting the pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Amgen, Roche and Johnson & Johnson have active therapeutic proteins pipelines. One of the major activities in the market at present is the development of generic versions of off-patent drugs. The entry of these generic versions will boost the therapeutic proteins market and thereby bring about further growth in the therapeutic proteins market in the coming years. The rapid entry of new players is set to intensify competition in this market.

The Therapeutic Proteins Market is Concentrated, with the Top Three Companies Having Significant Market Shares

The global therapeutic proteins market is dominated by three major pharmaceutical companies, which account for a significant percentage of the market. The top company is Roche, followed by Amgen and Novo Nordisk. Although three top companies dominate the market, there are also a number of small pharmaceutical companies in the market, making it a strong market in terms of competition. However, the development of blockbuster drugs has made these three companies the dominant players in the market. Roche markets Rituxan, Epogin, Herceptin, Pegasys, and Nutropin, and has total revenues of $22.4 billion; Amgen markets Aranesp, Neupogen, and Neulasta, and has total revenues of $19.7 billion; Novo Nordisk, through its drugs Novolin and Novolog, has total revenues of $8.6 billion in the therapeutic proteins market.

GBI Research, the leading business intelligence provider, has released its latest research, Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global therapeutic proteins market. The report analyzes the markets for therapeutic proteins in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. It includes sales forecasts until 2017 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies.

It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

For the purpose of this report, monoclonal antibodies have been included as a part of therapeutic proteins market along with blood factors, colony stimulating factors, erythropoietins, human growth hormone, insulin and interferons.

To purchase the report or for further information go to:

About GBI Research

GBI Research is a leading business information company providing global business information reports and services.

Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.


All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GBI Research.

The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GBI Research delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such GBI Research can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.


Have Your Say
Rate this feature and give us your feedback in the comments section below